pyrazines has been researched along with Mouth Neoplasms in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Axelrod, MJ; Bekiranov, S; David, AP; Donaldson, L; Dougherty, MI; Frierson, HF; Gioeli, DG; Hubbard, MA; Jameson, MJ; Khalil, AA; Lehman, CE; McGarey, PO; Mendez, RE; Petricoin, EF; Schoeff, SS; Stelow, EB; Taniguchi, LE; Wulfkuhle, JD | 1 |
| Ding, X; Matsuo, K; Xu, L; Yang, J; Zheng, L | 1 |
| Ackermann, H; Arnoldner, C; Baghi, M; Bisdas, S; Gstöttner, W; Hambek, M; Knecht, R; May, A; Wagenblast, J | 1 |
| Begum, NM; Kuribayashi, N; Miyamoto, Y; Nagai, H; Onoue, T; Tamatani, T; Tomizuka, Y; Uchida, D | 1 |
| Du, Z; Fan, M; Gu, W; Jiao, Y; Kim, JG; Nosrat, CA; Pavicevic, Z; Pfeffer, LM; Rao, SK; Rosebush, M; Samant, S | 1 |
| Burr, DA; Cai, P; Callaghan, MU; Cruz, PG; Fribley, AM; Jacobs, RR; Kaufman, RJ; Kirchhoff, PD; Larsen, MJ; Larsen, SD; Miller, JR; Narula, N; Neubig, RR; Ron, D; Schultz, PJ; Sherman, DH; Showalter, HD; Tamayo-Castillo, G | 1 |
| Fujisawa, K; Hara, K; Kinouchi, M; Kuribayashi, N; Miyamoto, Y; Nagai, H; Ohe, G; Takamaru, N; Tamatani, T; Uchida, D | 1 |
| Harada, K; Sato, M; Yoshida, H | 1 |
| Osaki, T; Ueta, E; Yamamoto, T; Yoneda, K | 1 |
9 other study(ies) available for pyrazines and Mouth Neoplasms
| Article | Year |
|---|---|
Antitumor effect of insulin-like growth factor-1 receptor inhibition in head and neck squamous cell carcinoma.
Topics: Head and Neck Neoplasms; Humans; Imidazoles; Insulin-Like Growth Factor I; Mouth Neoplasms; Neoplasm Staging; Pyrazines; Pyrazoles; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Triazines; Tumor Cells, Cultured | 2020 |
Optimized combinations of bortezomib, camptothecin, and doxorubicin show increased efficacy and reduced toxicity in treating oral cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Humans; Mouth Neoplasms; Pyrazines | 2015 |
Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Survival; Cetuximab; Esophageal Neoplasms; Fibroblasts; Humans; Mouth Neoplasms; Multiple Myeloma; Pyrazines | 2009 |
Vesnarinone downregulates CXCR4 expression via upregulation of Krüppel-like factor 2 in oral cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cisplatin; Down-Regulation; Flow Cytometry; Fluorouracil; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Kruppel-Like Transcription Factors; Luciferases; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Pyrazines; Quinolines; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Pro-inflammatory genes as biomarkers and therapeutic targets in oral squamous cell carcinoma.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Biomarkers; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cells, Cultured; Dose-Response Relationship, Drug; Gene Expression Profiling; Humans; Inflammation; Interleukin-8; Microarray Analysis; Mouth Neoplasms; NF-kappa B; Pyrazines; RNA, Small Interfering | 2010 |
Complementary cell-based high-throughput screens identify novel modulators of the unfolded protein response.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Caspases; Cell Proliferation; CHO Cells; Cricetinae; Drug Evaluation, Preclinical; eIF-2 Kinase; Eukaryotic Initiation Factor-2; Genes, Reporter; High-Throughput Screening Assays; Humans; Luciferases; Mouth Neoplasms; Mycotoxins; Pyrazines; Signal Transduction; Transcription Factor CHOP; Transduction, Genetic; Unfolded Protein Response | 2011 |
Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Female; Humans; I-kappa B Proteins; Interleukin-6; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Neoplasm Transplantation; Neovascularization, Pathologic; NF-kappa B; NF-KappaB Inhibitor alpha; Poly(ADP-ribose) Polymerases; Pyrazines; Radiation-Sensitizing Agents; Transcription Factor RelA; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Neovascularization, Pathologic; NF-kappa B; Protein Binding; Pyrazines; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2005 |
Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Differentiation; Cyclin E; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; G1 Phase; Humans; Mouth Neoplasms; Phosphorylation; Promoter Regions, Genetic; Pyrazines; Quinolines; Retinoblastoma Protein; RNA, Messenger; Transforming Growth Factor beta; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |